Učitavanje...
Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma
The oral multikinase inhibitor sunitinib malate was approved by the U.S. Food and Drug Administration in January 2006 for use in patients with advanced renal cell carcinoma (RCC). Since then, it has been approved globally for this indication and for patients with imatinib‐resistant or ‐intolerant ga...
Spremljeno u:
| Izdano u: | Oncologist |
|---|---|
| Glavni autori: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Wiley-Blackwell
2016
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5313263/ https://ncbi.nlm.nih.gov/pubmed/27807302 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0197 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|